FDA Guidance Urges Metabolite Testing Early In Drug Development Process
A new FDA guidance encourages evaluation of metabolites as early in the drug development process as is feasible, as metabolites that appear only in human plasma or at disproportionately higher levels in humans than in animals will require nonclinical toxicity studies and such studies should be done before large-scale clinical trials
You may also be interested in...
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.
NSF International has put its cosmetic product verification program on ice due to lack of interest since its launch in April 2017. Meanwhile, more than 1,000 products from 75+ brands have earned the "EWG Verified" mark, and the NGO says interest is higher than ever following Walmart's announcement in September that it will begin pushing vendors to pursue the verification.
Alexandra Kowcz is the Personal Care Product Council's new executive VP for science, effective Jan. 29, 2018. She brings to the trade association extensive experience from R&D and manager roles at Beiersdorf and P&G, as well as drug firms and cosmetic ingredient supplier Centerchem.